Hypertensive left ventricular hypertrophy: A mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance

Journal of Hypertension

Volumn 30, Issue 10, 2012, Pages 2039-2046

  Burns, Joanna ^a   Ball, Stephen G ^a   Worthy, Gillian ^b   Struthers, Allan D ^c   Mary, David A S G ^a   Greenwood, John P ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

arterial hypertension; cardiovascular magnetic resonance; left ventricular hypertrophy; renin angiotensin aldosterone system; sympathetic nervous system

Indexed keywords

AMLODIPINE; BENDROFLUMETHIAZIDE; MOXONIDINE; VALSARTAN;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 84866550934     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328356b850     Document Type: Article

References (46)

1. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
2. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793.
3. Yurenev AP, Dyakonova HG, Novikov ID, VitolsA, PahlL, Haynemann G. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: multicenter trial. Am J Hyper-tens 1992; 5 (pt 2):182S-189S.
4. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13:1091-1095.
5. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
6. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322:1561-1566.
7. Casale PN, Devereux RB, Milner M. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178.
8. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
9. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
10. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, et al. For the HOPE investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104:1615-1621.
11. Lauer MS, Anderson KM, Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol 1991; 18:1287-1294.
12. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, et al. Influence of arterial blood pressure and aldoster-one on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993; 71:17A-20A.
13. Harrap SB, Dominiczak AF, Fraser R, Lever AF, Morton JJ, Foy CJ, Watt GC. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996; 93:1148-1154.
14. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100:1802-1807.
15. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J 1998; 19 (Suppl F):F14-F18.
16. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of randomised doubleblind studies. JAMA 1996; 275:1507-1513.
17. Kaneko K, Susic D, Nunez E, Frohlich ED. ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Am J Med Sci 1997; 314:21-27.
18. Ainscough JF-X, Drinkhill MH, Sedo A, Turner NA, Brooke DA, Balmforth AJ, Ball SG, et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 2008; 81:592-600.
19. Folkow B. Physiological aspect of primary hypertension. Physiol Rev 1982; 62:347-504.
20. Julius S, Nesbitt S. Sympathetic overactivity in hypertension. A moving target. Am J Hypertens 1996; 9:113s-120s.
21. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha-1 adrenergic response. J Clin Invest 1983; 72:732-738.
22. Sen S, Tarazi RC. Cardiovascular hypertrophy in spontaneously hypertensive rats. J Hypertens Suppl 1986; 4:S123-S126.
23. Devereux RB, Dahlof B. Criteria for an informative trial of left ventricular hypertrophy regression. J Human Hypertens 1994; 8:735-739.
24. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992; 6:85-90.
25. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5:95-110.
26. Bellenger NG, Davies LC, Francis JM, Coates AJS, Pennell DJ. Reduction in sample size for studies of remodelling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000; 2:271-278.
27. Altman DG. Clinical trials. In: Altman DG, editor. Practical statistics for medical research. London, England: Chapman and Hall/CRC, 1999. pp. 440-445.
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206-1252.
29. Fieno DS, Jaffe WC, Simonetti OP, Judd RM, Finn JP. TrueFISP: assessment of accuracy for measurement of left ventricular mass in an animal model. J Cardiovasc Magn Reson 2002; 15:526-531.
30. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DASG, Greenwood JP. The relationship between central sympathetic drive and MRI determined left ventricular mass in essential hypertension. Circulation 2007; 115:1999-2005.
31. Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivananthan MU. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequence. J Magn Reson Imaging 2003; 17:323-329.
32. Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1999; 1:7-21.
33. Gaasch WH, Zile MR. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol 2011; 58:1733-1740.
34. Greenwood JP, Stoker JB, Mary DASG. Single unit sympathetic discharge: quantitative assessment in human hypertensive disease. Circulation 1999; 100:1305-1310.
35. Greenwood JP, Scott EM, Stoker JB, Mary DASG. Hypertensive left ventricular hypertrophy: relationship to peripheral sympathetic drive. J Am Coll Cardiol 2001; 38:1711-1717.
36. Greenwood JP, Scott EM, Stoker JB, Mary DA. Chronic I(1)-imidazoline agonism: sympathetic mechanisms in hypertension. Hypertension 2000; 35:1264-1269.
37. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihyper-tensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997; 95:2007-2014.
38. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13:564-569.
39. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papade-metriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110:1456-1462.
40. Weber KT, Brilla CG. Pathological hypertrophy and cardiac intersti-tium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83:1849-1865.
41. Marcus R, Krause L, Weder AB, Mejia AD, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecum-seh blood pressure study. Circulation 1994; 90:928-936.
42. Kelm M, Schäfer S, Mingers S, Heydthausen M, Vogt M, Motz W, Strauer BE. Left ventricular mass is linked to cardiac noradrenaline in normo-tensive and hypertensive patients. J Hypertens 1996; 14:1357-1364.
43. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
44. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713-720.
45. Binggeli C, Corti R, Sudano I, Luscher TF, Noll G. Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension 2002; 39:892-896.
46. Otterstad JE, Froeland G, St John Sutton M, Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 1997; 18:507-513.